Replies to post #2662 on VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

Why so. Plenty of major catalysts in the next 15 months. But even without price spikes pps is irrelevant and completely disconnected to value.

If VTGN continues success through adjunctive testing Big Pharma does not evaluate a buyout of a drug based on a company’s current pps, they do so based on a drugs projected sales revenue. 15 months from now, because I believe the data needs to be published, big pharma could be in a bidding war for AV101